CYT

Cyteir Therapeutics, Inc. [CYT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CYT Stock Summary

Top 10 Correlated Stocks

CYT


In the News

05:32 28 Mar 2024 CYT

Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise

Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being investigated in combination with chemotherapy drugs. The drug has shown monotherapy activity in a phase 1 trial, but further development has been suspended.

07:30 28 Mar 2024 CYT

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14 Time:

08:14 28 Mar 2024 CYT

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

04:30 28 Mar 2024 CYT

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The a

07:30 28 Mar 2024 CYT

Cyteir Therapeutics Selected to Join Russell 2000® Index

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 300

07:30 28 Mar 2024 CYT

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET. A live webcast of the fireside chat will be available in the I

07:30 28 Mar 2024 CYT

Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021. 12th Annual Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10 Time: 11:30 AM EDT Panel: Syn

05:00 28 Mar 2024 CYT

Cyteir Therapeutics Announces Closing of Initial Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional

CYT Financial details

Company Rating
Neutral
Market Cap
108.71M
Income
-30.88M
Revenue
0
Book val./share
3.47
Cash/share
3.59
Dividend
-
Dividend %
-
Employees
46
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-3.56
Forward P/E
-4.51
PEG
0.6
P/S
-
P/B
0.88
P/C
0.84
P/FCF
-4.21
Quick Ratio
21.66
Current Ratio
21.89
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-0.87
EPS next Y
-0.67
EPS next Q
1.58
EPS this Y
-41.59%
EPS next Y
-23.25%
EPS next 5Y
-23.25%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-59.17%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
57.38%
Inst Trans
-0.46%
ROA
-24%
ROE
-23%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
36M
Shs Float
10.83M
-
-
-
-
Target Price
2
52W Range
1.65-3.19
52W High
+0.67%
52W Low
+202%
RSI
44
Rel Volume
6.01
Avg Volume
167.62K
Volume
1.01M
Perf Week
0%
Perf Month
-2.27%
Perf Quarter
0.67%
Perf Half Y
8.63%
-
-
-
-
Beta
0.096
-
-
Volatility
0%, 0.04%
Prev Close
0.33%
Price
3.02
Change
0.33%

CYT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-0.77-0.87-2.14-1.25
Operating cash flow per share
-0.9-0.78-1.85-1.21
Free cash flow per share
-0.91-0.81-1.91-1.21
Cash per share
1.490.469.734.17
Book value per share
-1.46-2.019.614.15
Tangible book value per share
-1.46-2.019.614.15
Share holders equity per share
-1.46-2.019.614.15
Interest debt per share
0000.01
Market cap
338.14M415.69M221.71M58.2M
Enterprise value
309.13M404.75M31.98M-88.03M
P/E ratio
-22.48-19.96-5.32-1.32
Price to sales ratio
42.27K000
POCF ratio
-19.26-22.42-6.15-1.37
PFCF ratio
-19.12-21.44-5.96-1.36
P/B Ratio
-11.93-8.651.180.4
PTB ratio
-11.93-8.651.180.4
EV to sales
38.64K000
Enterprise value over EBITDA
-19.45-19.66-0.761.83
EV to operating cash flow
-17.61-21.83-0.892.07
EV to free cash flow
-17.47-20.88-0.862.05
Earnings yield
-0.04-0.05-0.19-0.76
Free cash flow yield
-0.05-0.05-0.17-0.74
Debt to equity
0000.01
Debt to assets
0000.01
Net debt to EBITDA
1.830.534.493.04
Current ratio
15.433.8725.7128.07
Interest coverage
00072.11
Income quality
1.170.890.860.92
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
418.13000
Research and developement to revenue
1.6K000
Intangibles to total assets
0000
Capex to operating cash flow
0.010.050.030.01
Capex to revenue
-16.63000
Capex to depreciation
-0.62-2.42-2.48-0.47
Stock based compensation to revenue
30.88000
Graham number
5.046.2821.4810.78
ROIC
0.570.44-0.22-0.31
Return on tangible assets
-0.48-1.52-0.21-0.29
Graham Net
-1.54-2.139.323.97
Working capital
28.47M8.99M185.57M143.89M
Tangible asset value
-28.34M-48.03M187.29M146.29M
Net current asset value
-29.27M-49.64M184.98M142.26M
Invested capital
0000.01
Average receivables
0113.5K50.5K19K
Average payables
01.15M1.74M1.46M
Average inventory
0598.5K-50.5K-19K
Days sales outstanding
7.48K000
Days payables outstanding
17.32K1.76K1.36K299.43
Days of inventory on hand
36.24K-65.51-28.960
Receivables turnover
0.05000
Payables turnover
0.020.210.271.22
Inventory turnover
0.01-5.57-12.610
ROE
0.530.43-0.22-0.3
Capex per share
-0.01-0.04-0.06-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.29-0.21-0.32-0.24-0.1
Operating cash flow per share
-0.36-0.2-0.29-0.12-0.13
Free cash flow per share
-0.36-0.2-0.29-0.12-0.13
Cash per share
4.364.163.863.743.59
Book value per share
4.364.143.793.583.47
Tangible book value per share
4.364.143.793.583.47
Share holders equity per share
4.364.143.793.583.47
Interest debt per share
0.010.02-0.0200
Market cap
67.83M58.37M64.77M92.93M102.33M
Enterprise value
-85.16M-87.86M-72.34M-40.64M-26.9M
P/E ratio
-1.64-1.97-1.4-2.76-7.24
Price to sales ratio
00000
POCF ratio
-5.4-8.44-6.37-22.4-22.46
PFCF ratio
-5.39-8.09-6.37-22.4-22.46
P/B Ratio
0.440.40.480.730.82
PTB ratio
0.440.40.480.730.82
EV to sales
00000
Enterprise value over EBITDA
7.358.745.644.285.32
EV to operating cash flow
6.7812.77.119.85.9
EV to free cash flow
6.7712.177.119.85.9
Earnings yield
-0.15-0.13-0.18-0.09-0.03
Free cash flow yield
-0.19-0.12-0.16-0.04-0.04
Debt to equity
0.010.01000
Debt to assets
0.010.01000
Net debt to EBITDA
13.214.5510.714.0625.53
Current ratio
27.0528.0734.9420.3521.89
Interest coverage
16.47287.2314.3400
Income quality
1.140.790.810.491.29
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.04000
Capex to revenue
00000
Capex to depreciation
-0.06-1.78000
Stock based compensation to revenue
00000
Graham number
5.364.415.264.352.77
ROIC
-0.07-0.06-0.09-0.08-0.04
Return on tangible assets
-0.06-0.05-0.08-0.06-0.03
Graham Net
4.143.963.743.553.42
Working capital
151.53M143.89M134.43M127.33M124.67M
Tangible asset value
154.03M146.29M134.98M127.79M125.03M
Net current asset value
149.69M142.26M134.39M127.31M124.67M
Invested capital
0.010.01000
Average receivables
114.5K8.5K126K173.5K56K
Average payables
2.64M1.4M901K1.01M923.5K
Average inventory
00-126K-173.5K-56K
Days sales outstanding
00000
Days payables outstanding
749.7311.41196.951.21K457.2
Days of inventory on hand
00-73.64-85.5-15.3
Receivables turnover
00000
Payables turnover
0.120.290.460.070.2
Inventory turnover
00-1.22-1.05-5.88
ROE
-0.07-0.05-0.09-0.07-0.03
Capex per share
0-0.01000

CYT Frequently Asked Questions

What is Cyteir Therapeutics, Inc. stock symbol ?

Cyteir Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol CYT

Is Cyteir Therapeutics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $2. The lowest prediction is $2 and the highest is $2

What is CYT stock prediction ?

What is Cyteir Therapeutics, Inc. stock quote today ?

Cyteir Therapeutics, Inc. stock price is $3.02 today.

Is Cyteir Therapeutics, Inc. stock public?

Yes, Cyteir Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap